scholarly journals Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma

2021 ◽  
Author(s):  
Jwa Hoon Kim ◽  
Shinkyo Yoon ◽  
Dae Ho Lee ◽  
Se Jin Jang ◽  
Sung‐Min Chun ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Lung Adenocarcinoma ◽  
Real World ◽  
Gene Analysis ◽  
Next Generation ◽  
Generation Sequencing

scholarly journals Mutation Profile of Resected EGFR ‐Mutated Lung Adenocarcinoma by Next‐Generation Sequencing

2019 ◽  
Vol 24 (10) ◽  
pp. 1368-1374 ◽  
Author(s):  
Ze‐Rui Zhao ◽  
Yao‐Bin Lin ◽  
Calvin S.H. Ng ◽  
Rong Zhang ◽  
Xue Wu ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Lung Adenocarcinoma ◽  
Next Generation ◽  
Mutation Profile ◽  
Egfr Mutated ◽  
Generation Sequencing

scholarly journals Next-Generation Sequencing Approach to Non–Small Cell Lung Carcinoma Yields More Actionable Alterations

2017 ◽  
Vol 142 (3) ◽  
pp. 353-357 ◽  
Author(s):  
Mitra Mehrad ◽  
Somak Roy ◽  
Humberto Trejo Bittar ◽  
Sanja Dacic
Keyword(s):  
Next Generation Sequencing ◽  
Lung Adenocarcinoma ◽  
Small Cell ◽  
Gene Panel ◽  
Next Generation ◽  
Small Cell Lung ◽  
Genomic Alterations ◽  
Generation Sequencing ◽  
Gene Alterations ◽  
Cancer Panel

Context.— Different testing algorithms and platforms for EGFR mutations and ALK rearrangements in advanced-stage lung adenocarcinoma exist. The multistep approach with single-gene assays has been challenged by more efficient next-generation sequencing (NGS) of a large number of gene alterations. The main criticism of the NGS approach is the detection of genomic alterations of uncertain significance. Objective.— To determine the best testing algorithm for patients with lung cancer in our clinical practice. Design.— Two testing approaches for metastatic lung adenocarcinoma were offered between 2012–2015. One approach was reflex testing for an 8-gene panel composed of DNA Sanger sequencing for EGFR, KRAS, PIK3CA, and BRAF and fluorescence in situ hybridization for ALK, ROS1, MET, and RET. At the oncologist's request, a subset of tumors tested by the 8-gene panel was subjected to a 50-gene Ion AmpliSeq Cancer Panel. Results.— Of 1200 non–small cell lung carcinomas (NSCLCs), 57 including 46 adenocarcinomas and NSCLCs, not otherwise specified; 7 squamous cell carcinomas (SCCs); and 4 large cell neuroendocrine carcinomas (LCNECs) were subjected to Ion AmpliSeq Cancer Panel. Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%). Four SCCs and 2 LCNECs showed investigational genomic alterations. Conclusions.— The NGS approach would result in the identification of a significant number of actionable gene alterations, increasing the therapeutic options for patients with advanced NSCLCs.

scholarly journals 386P Oncogenic fusions in CNS gliomas assessed by next generation sequencing: The real-world experience

2020 ◽  
Vol 31 ◽  
pp. S405-S406
Author(s):  
J. Polivka ◽  
M. Svajdler ◽  
V. Priban ◽  
P. Martinek ◽  
N. Ptakova ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Real World ◽  
Next Generation ◽  
The Real ◽  
Generation Sequencing

scholarly journals Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0224379 ◽  
Author(s):  
You Jin Chun ◽  
Jae Woo Choi ◽  
Min Hee Hong ◽  
Dongmin Jung ◽  
Hyeonju Son ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Lung Adenocarcinoma ◽  
Molecular Characterization ◽  
Next Generation ◽  
Korean Patients ◽  
Generation Sequencing
Sign in / Sign up

Export Citation Format

Share Document